• Consensus Rating: Reduce
  • Consensus Price Target: $12.08
  • Forecasted Upside: 15.85%
  • Number of Analysts: 7
  • Breakdown:
  • 2 Sell Ratings
  • 4 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$10.43
▲ +0.03 (0.29%)

This chart shows the closing price for EHAB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Enhabit Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EHAB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EHAB

Analyst Price Target is $12.08
▲ +15.85% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Enhabit in the last 3 months. The average price target is $12.08, with a high forecast of $15.00 and a low forecast of $9.50. The average price target represents a 15.85% upside from the last price of $10.43.

This chart shows the closing price for EHAB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Reduce

The current consensus among 7 polled investment analysts is to reduce stock in Enhabit. This Reduce consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 2 sell ratings
10/23/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 2 sell ratings
1/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 2 sell ratings
4/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 2 sell ratings
7/20/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 2 sell ratings
10/18/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 2 sell ratings
1/16/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 2 sell ratings
3/16/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 2 sell ratings
4/15/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/7/2024OppenheimerReiterated RatingMarket Perform ➝ Market PerformLow
3/7/2024UBS GroupUpgradeSell ➝ Neutral$9.50Low
3/6/2024Jefferies Financial GroupLower TargetBuy ➝ Buy$15.00 ➝ $14.00Low
12/12/2023TD CowenInitiated CoverageMarket Perform$12.00Low
8/11/2023Credit Suisse GroupLower TargetNeutral ➝ Neutral$15.00 ➝ $12.00Low
6/20/2023SVB LeerinkReiterated RatingUnderperformLow
6/20/2023SVB SecuritiesInitiated CoverageUnderperform$10.00Low
5/12/2023CitigroupLower Target$18.00 ➝ $15.00Low
3/16/2023The Goldman Sachs GroupInitiated CoverageNeutral$15.00Low
2/17/2023CitigroupBoost TargetNeutral$16.00 ➝ $18.00Low
2/16/2023Credit Suisse GroupReiterated RatingNeutral$15.00Low
2/15/2023Stifel NicolausBoost Target$17.00 ➝ $18.00Low
12/13/2022CJS SecuritiesInitiated CoverageMarket Perform$18.00Low
12/8/2022UBS GroupInitiated CoverageSell$12.00Low
12/5/2022Stifel NicolausInitiated CoverageBuy$17.00Low
11/4/2022Credit Suisse GroupLower TargetNeutral$19.00 ➝ $15.00N/A
10/13/2022OppenheimerInitiated CoverageMarket PerformLow
8/30/2022Jefferies Financial GroupInitiated CoverageBuy$20.00Low
8/25/2022Credit Suisse GroupInitiated CoverageNeutral$19.00Low
8/18/2022CitigroupInitiated CoverageNeutral$17.00Low
7/13/2022Bank of AmericaInitiated CoverageUnderperform$16.00N/A
(Data available from 4/16/2019 forward)

News Sentiment Rating

0.81 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/18/2023
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/18/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/17/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/17/2023
  • 4 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/16/2024
  • 5 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/15/2024
  • 12 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
3/16/2024
  • 5 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/15/2024

Current Sentiment

  • 5 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Enhabit logo
Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was founded in 1998 and is based in Dallas, Texas.
Read More

Today's Range

Now: $10.43
Low: $10.17
High: $10.48

50 Day Range

MA: $10.11
Low: $7.81
High: $11.65

52 Week Range

Now: $10.43
Low: $7.12
High: $14.59

Volume

459,845 shs

Average Volume

597,166 shs

Market Capitalization

$523.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.96

Frequently Asked Questions

What sell-side analysts currently cover shares of Enhabit?

The following Wall Street sell-side analysts have issued stock ratings on Enhabit in the last year: Citigroup Inc., Credit Suisse Group AG, Jefferies Financial Group Inc., Oppenheimer Holdings Inc., SVB Leerink LLC, SVB Securities, TD Cowen, TheStreet, and UBS Group AG.
View the latest analyst ratings for EHAB.

What is the current price target for Enhabit?

6 Wall Street analysts have set twelve-month price targets for Enhabit in the last year. Their average twelve-month price target is $12.08, suggesting a possible upside of 15.9%. Citigroup Inc. has the highest price target set, predicting EHAB will reach $15.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $9.50 for Enhabit in the next year.
View the latest price targets for EHAB.

What is the current consensus analyst rating for Enhabit?

Enhabit currently has 2 sell ratings, 4 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for EHAB.

What other companies compete with Enhabit?

How do I contact Enhabit's investor relations team?

The company's listed phone number is 214-239-6500 and its investor relations email address is [email protected]. The official website for Enhabit is www.ehab.com. Learn More about contacing Enhabit investor relations.